KIM-1 is a transmembrane glycoprotein that sits quietly on the surface of healthy kidney cells, essentially invisible in the urine of a healthy person. When the proximal tubules, the kidney’s reabsorption workhorses, suffer ischemic or toxic injury, KIM-1 expression surges dramatically. In healthy individuals, urinary KIM-1 concentrations remain below one nanogram per milliliter, but after ischemic renal injury they can climb to three to seven nanograms per milliliter. That fold-change, combined with the molecule’s tight association with tubular damage, inflammation, and renal fibrosis, has earned KIM-1 recognition as a sensitive and specific urinary biomarker from both the U.S. Food and Drug Administration and the European Medicines Agency. Because kidney tissue has limited regenerative capacity once injured, catching that molecular distress signal early is not merely convenient; it can determine whether a patient’s kidneys recover or progress toward chronic failure.

The problem has been turning that biological promise into a practical measurement. Conventional laboratory assays for KIM-1 rely on instrumentation that is expensive, centralized, and slow, which is a poor fit for a condition whose clinical value depends on speed. The Turkish team, led by Meltem Afşar and Mustafa Kemal Sezgintürk, took a different route. They started with electrodes made of indium tin oxide coated onto polyethylene terephthalate, the same transparent conductive film used in touchscreens and flexible displays. ITO-PET electrodes are semiconductive, electrically conductive, mechanically flexible, and, crucially, disposable and cheap to fabricate. A sensor built on such a platform could, in principle, be used once and thrown away, eliminating the cross-contamination risks and cleaning burdens that plague reusable clinical electrodes.

The heart of the innovation lies in the surface chemistry. The researchers first treated the ITO-PET strips with a cleaning sequence and then with a solution of ammonium hydroxide, hydrogen peroxide, and water to blanket the surface with hydroxyl groups. Onto this activated surface they deposited carboxyethylsilanetriol, or CTES, a trifunctional silane whose silanol groups condense with the surface hydroxyls to form stable covalent silicon-oxygen-metal bonds. The result is a self-assembled monolayer that is densely packed, chemically robust, and negatively charged, with carboxyl groups left dangling and exposed like molecular Velcro. Those carboxyl groups were then activated with classic EDC/NHS carbodiimide chemistry, converting them into reactive esters that latch onto the amine groups of the anti-KIM-1 antibody, forming strong amide bonds. A final blocking step with bovine serum albumin sealed off any remaining sticky patches, ensuring that only genuine antibody-antigen binding would register as a signal.

Every step of this construction was tracked electrochemically using cyclic voltammetry and electrochemical impedance spectroscopy, a technique that measures how much the electrode resists the flow of electrons through a redox probe solution. The team fitted their impedance spectra to a modified Randles equivalent circuit and used the charge transfer resistance, Rct, as the analytical readout. The progression told a coherent story: hydroxylation lowered the resistance to 1100 ohms by boosting conductivity, the CTES monolayer dropped it further to 670 ohms, and then each added biomolecular layer, the EDC/NHS ester at 1383 ohms, the antibody at 1450 ohms, and the BSA block at 1485 ohms, progressively impeded electron transfer as insulating protein stacked up on the surface. When KIM-1 antigen bound to the antibody, resistance rose again in a concentration-dependent fashion, from 169 ohms at 0.01 nanograms per milliliter to 4846 ohms at 2.5 nanograms per milliliter. Each bound antigen molecule thickens the insulating biolayer, making it harder for the ferri/ferrocyanide probe to reach the electrode, and that growing barrier is the signal.

Atomic force microscopy provided an independent, visual confirmation of the story the electrochemistry told. Scanning five-by-five micrometer patches of the electrode in non-contact mode, the researchers watched the surface roughness rise after CTES modification and antibody immobilization, fall as BSA smoothed over the gaps, and rise once more when KIM-1 bound to the waiting antibodies. The morphological changes at each stage matched the impedance data, a satisfying convergence that strengthens confidence that the sensor works exactly as designed. The team also subjected their impedance measurements to Kramers-Kronig transformation, a mathematical consistency check that verifies the real and imaginary components of the impedance data belong to the same physical system, ensuring the measurements were internally reliable.

Optimization was exhaustive. The researchers systematically varied the CTES concentration, finding that 0.05 percent produced the best balance between too sparse a monolayer and one so dense it blocked antigen access. They tested EDC/NHS concentrations and settled on 0.04 millimolar EDC with 0.01 millimolar NHS, noting that higher concentrations caused signal distortion from random antibody binding. The activation chemistry worked best at neutral pH, consistent with the known reactivity window of NHS esters, and 45 minutes proved the sweet spot for both the crosslinking step and the antibody incubation. Antibody concentration mattered too: five nanograms per milliliter was too little, twenty caused steric hindrance, and ten nanograms per milliliter was just right. The final calibration equation, relating KIM-1 concentration to the change in charge transfer resistance, emerged from this painstaking tuning.

The analytical performance figures are impressive for such a simple platform. The sensor responds across a working range of 0.01 to 2.5 nanograms per milliliter, with a limit of detection of 0.22 nanograms per milliliter and a limit of quantification of 0.74 nanograms per milliliter, numbers that sit squarely in the clinically relevant zone given that healthy urinary KIM-1 stays below one nanogram per milliliter. Twenty identically fabricated electrodes tested against a 0.5 nanogram per milliliter KIM-1 solution returned a mean reading of 0.502 nanograms per milliliter with a coefficient of variation of just 0.073 percent, a repeatability figure that would flatter far more elaborate instruments. Reproducibility across ten separately built sensors showed a relative standard deviation of 19.62 percent in slope values, which the authors attribute to manual fabrication but judge acceptable for a hand-assembled platform. The electrodes held stable performance for eight weeks of refrigerated storage, could be regenerated up to four times with brief hydrochloric acid washes before surface degradation set in, and shrugged off interference from creatine kinase, D-glucose, prostate-specific antigen, and bovine serum albumin.

Real-sample testing provided the crucial proof of concept. The team spiked five commercially available bovine urine samples, diluted a hundredfold, with KIM-1 at 0.25 and 1 nanogram per milliliter and measured recovery using the standard addition method, obtaining accurate and reliable values in triplicate. The authors are candid about the limitation: bovine urine does not fully mimic human urine biochemistry, and the anti-KIM-1 antibody is specific to the human protein, so validation with genuine human clinical samples remains the necessary next step. Long-term storage behavior beyond eight weeks and adaptation to routine clinical workflows, including standardization and large-scale fabrication, also await further study. Still, compared with other reported KIM-1 platforms, from nanocomposite-enhanced electrochemical sensors built on covalent organic frameworks and gold nanoparticles to sophisticated optical fiber interferometers, the ITO-PET immunosensor achieves competitive sensitivity with a streamlined fabrication protocol of roughly five main steps and no exotic nanomaterials.

The broader significance of this work extends beyond one biomarker. Kidney diseases now rank as the seventh leading cause of mortality worldwide, and their global prevalence continues to climb, placing enormous strain on healthcare systems that still depend on delayed creatinine measurements. A disposable, flexible, inexpensive electrode that can be functionalized with a silane monolayer and an antibody in an afternoon offers a template for point-of-care diagnostics that could be deployed in emergency departments, intensive care units, and resource-limited clinics alike. If subsequent clinical validation confirms what the laboratory data suggest, the humble plastic strip at the center of this study could help shift kidney injury detection from a retrospective diagnosis to a real-time warning, giving clinicians the head start they have long needed to protect one of the body’s most irreplaceable organs.

Subject of Research: Electrochemical immunosensor for detecting the kidney injury biomarker KIM-1 using silane-modified disposable ITO-PET electrodes

Article Title: Sensitive impedimetric immunosensing of kidney injury molecule 1 using carboxyethylsilanetriol modified indium tin oxide polyethylene terephthalate electrodes

Article References: Sensitive impedimetric immunosensing of kidney injury molecule 1 using carboxyethylsilanetriol modified indium tin oxide polyethylene terephthalate electrodes. (n.d.). https://doi.org/10.1007/s44373-026-00129-y

Image Credits: AI Generated

DOI: 10.1007/s44373-026-00129-y

Keywords: KIM-1, acute kidney injury, biosensor, electrochemical impedance spectroscopy, ITO-PET electrode, immunosensor, carboxyethylsilanetriol, EDC/NHS chemistry, urinary biomarker, self-assembled monolayer, point-of-care diagnostics, kidney disease

A research team led by Marcos Vilas Boas Filho and Valber de Albuquerque Pedrosa at São Paulo State University (UNESP) in Botucatu, Brazil, working with colleagues at the same institution, has now demonstrated a compact alternative: an electrochemical immunosensor built on a bioconjugated gold electrode that can generate melatonin-associated signals directly in homogenized kidney, liver, and heart tissue from laboratory rats. Published in Discover Electrochemistry, the study is billed as the first proof-of-concept demonstration of electrochemical immunosensing for melatonin in extrapineal tissue. Rather than seeking the lowest detection limit in the field, the team set out to show that antibody-based molecular recognition could be married to electrochemical transduction in matrices as chemically hostile as tissue homogenates.

The analytical chemistry underlying conventional melatonin measurement is well established. Techniques such as chemiluminescence, fluorometry, ultraviolet–visible spectrophotometry, gas chromatography–mass spectrometry, and high-performance liquid chromatography all deliver robust performance, but they demand multiple instrumental platforms, labor-intensive preparation, and long analysis times. Melatonin’s intrinsic photoreactivity compounds the difficulty, requiring manipulation under light-restricted conditions to prevent degradation. Electrochemical biosensors have emerged as attractive alternatives because of their low detection limits, operational simplicity, and rapid response, and recent years have seen nanostructured platforms achieve impressively low limits of detection in serum, urine, food, and pharmaceutical samples. A paper-based graphite electrode, a molecularly imprinted polymer platform, and a sensor incorporating core–shell Cu@Pt nanoparticles have all reported submicromolar detection. But nearly all of these rely on the direct electrochemical oxidation of melatonin, an approach vulnerable to electrode fouling, matrix interference, and overlapping signals from other electroactive compounds—and none had been applied to extrapineal tissue.

The Brazilian team’s strategy inverts that logic. Instead of oxidizing melatonin directly, they built an indirect sensing architecture in which the hormone is captured by an immobilized antibody, and its presence is read out as a measurable suppression of a redox probe’s current. The fabrication begins with a gold electrode 1.7 millimeters in diameter, onto which a self-assembled monolayer of 11-mercaptoundecanoic acid is formed by gold–sulfur bonding, exposing terminal carboxyl groups. These groups are then activated with the classic EDC/NHS coupling chemistry, generating reactive NHS-esters that covalently link to free amine groups on a polyclonal anti-melatonin antibody during overnight incubation at 4 degrees Celsius. The result is the Au/SAM-MUA/anti-ME interface: a stable, antibody-decorated surface in which every subsequent molecular event translates into an electrical signature.

Characterization of the assembly followed the standard toolbox of electroanalytical science. Cyclic voltammetry using the ferricyanide/ferrocyanide couple as a redox probe showed a progressive decline in peak current as each layer was added, confirming that the growing protein and organic films were hindering electron transfer as designed. Electrochemical impedance spectroscopy told the same story quantitatively: the charge-transfer resistance of the bare gold electrode stood at just 5 kilo-ohms, rising to 13 kilo-ohms after monolayer formation, 29 kilo-ohms after EDC/NHS activation, 30 kilo-ohms after antibody immobilization, and a marked 40 kilo-ohms once melatonin bound to the antibody layer. That final jump, the team notes, is the analytical heart of the device—each melatonin molecule captured at the surface adds insulating mass, physically blocking diffusion of the redox probe and deepening the measurable signal.

With square-wave voltammetry optimized at a frequency of 100 hertz, a step potential of 5 millivolts, and a pulse amplitude of 20 millivolts, the researchers calibrated the sensor against commercial melatonin standards across a linear range of 20 to 120 micromolar. The calibration curve carried a negative slope of –0.0034, exactly what the suppression mechanism predicts: the blank current of 0.59 microamperes fell to 0.18 microamperes at 120 micromolar melatonin. The derived figures of merit were a limit of detection of approximately 4 micromolar, a limit of quantification of 14 micromolar, and a striking electrochemical sensitivity of 250 microamperes per micromolar per square centimeter—among the highest sensitivities reported for any electrochemical melatonin platform, and the second highest overall. Recovery analysis with spiked samples reached 99.8 percent, and the sensor held 96.3 percent of its signal between consecutive measurement days, retaining functional integrity for up to eight days before the biological layer required re-immobilization.

Selectivity testing against common biological interferents revealed both strengths and honest limits. Serotonin, dopamine, and uric acid each shifted the redox signal by only 0.8 to 4.0 percent, well within acceptable tolerances. But ascorbic acid alone produced a 9.5 percent suppression, and a mixture of all interferents together caused an 11 percent deviation—statistically significant and a reminder that nonspecific matrix effects can creep into any antibody-based measurement in complex fluids. The authors attribute this partly to possible conformational changes in the antibody at certain pH values, which may partially expose the underlying electrode surface to blocking by other molecules. They are careful to frame the sensor’s selectivity as demonstrable but not yet definitive under all biological conditions.

The biological application was where the platform earned its novelty claim. Thirty male Wistar rats were divided into a treated group receiving intraperitoneal melatonin at 25 milligrams per kilogram three times weekly for four weeks, and a control group receiving saline. Liver, heart, and kidney samples were harvested, homogenized, and spiked with a known melatonin standard before analysis. Across all three tissues, successive additions of homogenate produced the characteristic progressive suppression of the ferri/ferrocyanide anodic current, and tissues from melatonin-treated animals consistently generated stronger current suppression than control samples. Kidney homogenates produced the greatest effect, followed by heart and liver—a pattern the researchers note aligns with known physiology, since the kidney is central to eliminating melatonin metabolites, the liver metabolizes the hormone via cytochrome P450 enzymes, and cardiac tissue harbors extrapineal melatonin and receptors tied to cardiovascular regulation.

The team is appropriately measured about what the tissue data mean. Because the current-response plots in the homogenates lacked sufficient linearity to derive formal detection limits for those matrices, and because no direct comparison with HPLC or LC–MS/MS was performed, the tissue signals are presented strictly as preliminary, qualitative proof-of-concept responses rather than precise quantifications. Still, the implications are considerable. The work establishes, for the first time, that an antibody-functionalized electrochemical interface can register melatonin-associated differences in kidney, liver, and heart tissue—opening a path toward rapid, point-of-care monitoring of hormone distribution in contexts where chromatography is impractical. The researchers say future work will focus on validating the platform against established chromatographic methods and implementing matrix-matched calibration to sharpen quantitative accuracy, potentially extending the technology to studies of circadian biology, neurodegenerative disease research, and antioxidant therapy monitoring where melatonin’s reach beyond the brain matters most.

The choice of an indirect immunosensing format carries practical implications worth underscoring. Because melatonin itself is not oxidized at the electrode surface, the many electroactive species that populate tissue homogenates—ascorbate, urate, catecholamines—compete far less directly for the analytical signal. The trade-off is kinetic and structural: antibody–antigen binding is slower than a simple electron-transfer event, and the biological recognition layer is inherently fragile, which is why the team found the interface required re-immobilization after roughly eight days of use. Such operational lifetimes are typical of protein-based sensors and represent a genuine engineering constraint for any future field deployment.

The tissue-specific response pattern observed in the rat study also merits interpretation. The strongest suppression in kidney homogenates is consistent with the organ’s role as the principal route of melatonin metabolite excretion, while the hepatic signal reflects cytochrome P450-mediated metabolism, the dominant catabolic pathway for the hormone in mammals. Cardiac tissue, meanwhile, is of particular interest because melatonin receptors expressed in myocardium have been linked to blood pressure regulation and cardioprotection, making a rapid tissue-level assay potentially valuable in cardiovascular research.

Methodologically, the spiking approach used in the proof-of-concept experiments deserves note. By adding a known commercial melatonin standard to each homogenate, the researchers could verify that the antibody layer remained functional even amid the proteins, lipids, and salts of a crude tissue matrix. The absence of a chromatographic cross-check, however, means the absolute endogenous concentrations in treated versus control animals remain unknown. Establishing that correlation, alongside matrix-matched calibration curves, will be the decisive next step in determining whether this bioconjugated gold interface can evolve from a qualitative indicator of melatonin-associated tissue responses into a genuinely quantitative analytical instrument for circadian and biomedical research.

Subject of Research: Development of a bioconjugated gold electrochemical immunosensor for detecting melatonin in extrapineal rat tissues

Article Title: Electrochemical melatonin detection in extrapineal tissue using a bioconjugated sensor

Article References: Filho, M. V. B., Agneis, M. L. G., de Souza, M. C., Gavioli, V. D., de Castro, G. R., Seiva, F. R. F., de Almeida Chuffa, L. G., & de Albuquerque Pedrosa, V. (2026). Electrochemical melatonin detection in extrapineal tissue using a bioconjugated sensor. Discover Electrochemistry, 3(1), Article 75. https://doi.org/10.1007/s44373-026-00162-x

Image Credits: AI Generated

DOI: 10.1007/s44373-026-00162-x

Keywords: melatonin, immunosensor, electrochemistry, biosensor, gold electrode, extrapineal tissue, square-wave voltammetry, electrochemical impedance spectroscopy, Wistar rats, circadian rhythm, antioxidant, tissue homogenate